Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>Hang Seng announced six immediate Connect ADDs and zero DELETEs, effective 8 Jun 2026. Three delayed ADDs remain outside this study pending stock splits.</li>
<li>Our 4 May forecast called five of six ADDs correctly.</li>
<li>Pre-Announcement cohort return matched history, but stock dispersion was far wider than prior cycles. Opening-gap size should drive bridge-window entry.</li>
</ul>


Hang Seng announced six immediate Connect ADDs and zero DELETEs, effective 8 Jun 2026. Three delayed ADDs remain outside this study pending stock splits.
Our 4 May forecast called five of six ADDs correctly.
Pre-Announcement cohort return matched history, but stock dispersion was far wider than prior cycles. Opening-gap size should drive bridge-window entry.


HSCI / HK Connect June 2026 Implementation: Post-Announcement Positioning

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Shenzhen Edge Medical / Equity Capital Markets

<ul>
<li>MP1000 has strong technical strength, setting it apart from Toumai. SP1000’s advantages are more obvious and the competitive landscape is also better than multi-port surgical robots, indicating corner overtaking opportunity.</li>
<li>With favorable policy support, <a href="https://www.smartkarma.com/entities/shenzhen-edge-medical-co-ltd" target="_blank" data-smartkarma-citation="entities:35912:1" rel="noopener">Shenzhen Edge Medical (SEM HK)</a> is embracing a golden opportunity. But the commercialization outlook of surgical robots in China is actually not optimistic.</li>
<li>As a later-comer in surgical robots industry, without the synergy from parent company, Edge’s future sales performance could be even weaker. So, its valuation should be lower than Medbot.</li>
</ul>


MP1000 has strong technical strength, setting it apart from Toumai. SP1000’s advantages are more obvious and the competitive landscape is also better than multi-port surgical robots, indicating corner overtaking opportunity.
With favorable policy support, Shenzhen Edge Medical (SEM HK) is embracing a golden opportunity. But the commercialization outlook of surgical robots in China is actually not optimistic.
As a later-comer in surgical robots industry, without the synergy from parent company, Edge’s future sales performance could be even weaker. So, its valuation should be lower than Medbot.


Pre-IPO Shenzhen Edge Medical - The Surgical Robot Business in China Is Proving Harder than Expected

China

Edge Medical specializes in the design, development, manufacturing, and sale of advanced surgical robot systems, including multi-port and single-port endoscopic robots and bronchoscopy systems. The company aims to advance surgical technologies and deliver high-quality robotic solutions to healthcare institutions globally. It was founded in Shenzhen, China, on May 4, 2017.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shenzhen Edge Medical (2675 HK)

HSCI / HK Connect June 2026 Implementation: Post-Announcement Positioning

HSCI / HK Connect June cycle is post-announcement. Six ADDs enter the bridge window with no DELETEs. Opening-gap discipline matters, alongside...

Ke Yan, CFA, FRM

Pre-IPO Shenzhen Edge Medical - The Surgical Robot Business in China Is Proving Harder than Expected

Surgical robots is always a hot field, but even with favorable policy, it’s difficult to make profits in China. Edge's commercialization outlook is...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)